The paradigm of using targeted molecular therapies against known aberrant signaling pathways is revolutionizing modern treatment of many cancers. In hepatocellular carcinoma, the use of sorafenib, a multikinase inhibitor, has improved survival in advanced disease. However, many other promising drugs have failed to improve on its success. This chapter summarizes the key mechanisms of pathway deregulation identified in cancer, and describes those pathways implicated in HCC carcinogenesis and progression. Current and potential future therapeutics targeting these pathways are discussed.

Original languageEnglish
Title of host publicationSignaling Pathways in Liver Diseases
Subtitle of host publicationThird Edition
Number of pages13
ISBN (Electronic)9781118663387
ISBN (Print)9781118663394
StatePublished - 28 Sep 2015


  • Biomarker
  • Liver cancer
  • Molecular cascade
  • Oncogene addiction
  • Personalized medicine
  • Stratified medicine


Dive into the research topics of 'Signaling in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this